a listed company is not evaluated for the forecasts / promises of its CEO (unless the CEO has international relevance and proven reliability).
Our (ridiculous) quotation today reflects both the objective data (few) released by the company, and the lack of independent analysis with consequent lack of interest in the market, and the lack of communication by the company. theoretically we should be worth 10 times as much for Excellagen alone, and it is clear that the explosive upside potential is enormous: the first positive news of some depth could get us to the dollar in an instant.
We capitalize less than 27 million, nothing, at 1 $ we would capitalize around 120 million ... Everything is in Moscato's hands: we small shareholders can sell and absorb a huge loss (in the majority of cases) or continue to trust him (another question that runs in the head: Moscato deserves our trust, considering communication put in place by him in the last 3 years?) Obviously it's my thought .....
Generex Biotechnology Corp. (GNBT) Stock Research Links